RxDoctor Payments Data

Kayla Mohr, MD

Dermatology · Little Rock, ARNPI 1992159156

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.2% of the total across 471 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 14.4% — the pattern of someone who eats at a lot of different presentations.

$8,865in general payments, 2019–2025

Across 471 payments — averaging $18.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$1K
  • AbbVie$1K
  • Novartis$1K
  • Sun Pharmaceutical Industries Inc.$922
  • Johnson & Johnson$824
  • Regeneron Healthcare Solutions, Inc.$723
  • plus $3K from 19 others

What the payments were for

  • Food & beverage$8,53096%
  • Education$3354%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,865 in reported general payments places this provider in the 80th percentile of 75 dermatology providers in Arkansas.

See all dermatology providers in Arkansas

Medicare billing

Part B allowed, 2024
$282,302
Medicare patients
691
Services billed
3,860

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab31$381,176
Skyrizi PenRisankizumab-Rzaa14$279,719
Taltz AutoinjectorIxekizumab29$198,957
Cosentyx Sensoready (2 Pens)Secukinumab12$128,237
Cosentyx Unoready PenSecukinumab11$121,792
Dupixent PenDupilumab26$97,632
Dupixent SyringeDupilumab12$45,876
Ketoconazole458$7,400
Fluocinonide153$6,445
Clobetasol Propionate141$6,038
Fluorouracil41$2,756
Tacrolimus33$2,128
Ciclopirox34$1,461
Metronidazole25$1,322
Triamcinolone Acetonide132$1,285

Paid to pharmacies, not to this prescriber.

Other dermatology in Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →